On 1 May 2026, Aurobindo announced that its subsidiary, CuraTeQ Biologics, received Canadian approval for Bevqolva™ (bevacizumab), biosimilar to Genentech’s Avastin®. Bevqolva™ is indicated for various cancers and is available in 100 mg and 400 mg formulations.
CuraTeQ received approval for Bevqolva™ in the UK in December 2024 and the product is currently under regulatory review in Europe.
Bevacizumab biosimilars have been approved and available in Canada for many years, including Amgen’s Mvasi® (approved April 2018), Biocon’s Abevmy® (launched May 2022), Samsung Bioepis/Organon’s Aybintio® (launched November 2022) and Celltrion’s Vegzelma™ (approval announced January 2023).
The first bevacizumab biosimilar was approved in the US in September 2017 and in Europe in January 2018.